Fast Facts Measurable Residual Disease
Download Fast Facts Measurable Residual Disease full books in PDF, epub, and Kindle. Read online free Fast Facts Measurable Residual Disease ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : J. Loke |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 33 |
| Release | : 2021-01-26 |
| Genre | : Medical |
| ISBN | : 331806825X |
Conventional methods of detecting disease remission in cancers such as leukemia rely on microscopic analysis of tissue samples. Measurable (or minimal) residual disease (MRD) describes the presence of disease beyond the levels of sensitivity afforded by microscopy. Fast Facts: Measurable Residual Disease describes what is meant by MRD, the opportunities and challenges afforded by its identification and the advantages and disadvantages of the methods used for its detection. Specific examples are given to illustrate the implications of detecting MRD in different disease scenarios, with emphasis on acute myeloid and lymphoblastic leukemias. With the recognition and monitoring of MRD likely to play an increasingly important role in disease prognosis and subsequent treatment direction, this accessible resource is ideal for any healthcare professional wanting to know more about this exciting and fast-moving area. Table of Contents: • What is measurable residual disease? • How is MRD measured? • What is the significance of MRD?
| Author | : William Blum |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 90 |
| Release | : 2018-05-14 |
| Genre | : Medical |
| ISBN | : 1910797596 |
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: • Epidemiology, pathophysiology and etiology • Diagnosis • Treatment • Supportive care • Prognosis and monitoring • Emerging treatments • Useful resources
| Author | : Donal McLornan |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 102 |
| Release | : 2022-04-25 |
| Genre | : Medical |
| ISBN | : 3318070807 |
Myelofibrosis is a myeloproliferative neoplasm that has markedly heterogeneous features. The clinical phenotype can range from initial indolent presentation, which may be stable for many years, through to marked cytopenias, debilitating constitutional symptoms, massive splenomegaly and an inherent risk of leukemic transformation. Despite many advances regarding molecular classification, prognostication models and rapeutic options over the last few decades, allogeneic stem cell transplantation remains the only curative option, yet is suitable only for a minority of patients. ‘Fast Facts: Myelofibrosis’ is written for health professionals by two leading experts in the field, and provides up-to-date guidance on its accurate diagnosis, risk stratification and management. It also provides key insights into the molecular biology underpinning the disease. This concise handbook is an indispensable read for anyone wanting to get up to speed with best practice in the diagnosis and care of people with myelofibrosis. Table of Contents: • Presentation, classification and epidemiology • Molecular biology and pathogenesis • Clinical assessment and diagnosis • Prognostic models • Treatment approaches • Allogeneic stem cell transplantation • Management of blast-phase myelofibrosis • Therapies in development
| Author | : Toby A. Eyre |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 80 |
| Release | : 2023-06-07 |
| Genre | : Medical |
| ISBN | : 3318072303 |
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. Table of Contents • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
| Author | : T.A. Eyre |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 74 |
| Release | : 2022-02-11 |
| Genre | : Medical |
| ISBN | : 3318069744 |
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. 'Fast Facts: Chronic Lymphocytic Leukemia' covers the epidemiology, etiology, diagnosis and staging of the disease, and the molecular and genetic aspects that underpin treatment and prognosis. It provides a concise overview of treatment options, in both the front-line and relapsed/refractory settings, with particular focus on the novel targeted agents that have overcome many adverse prognostic factors, improving overall survival. Table of Contents: • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
| Author | : E. Deconinck |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 54 |
| Release | : 2021-02-12 |
| Genre | : Medical |
| ISBN | : 3318068071 |
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare fast-growing hematodermic neoplasm that most often occurs in older men. It is notable for its highly aggressive behavior, with cutaneous, lymph node and bone marrow involvement. In the past, BPDCN has been poorly understood, recognized and treated, and consequently has had a poor prognosis. Today, it has been reclassified as a myeloid neoplasm and there is greater understanding of the disease’s clinical features, course and pathology, a new diagnostic test that makes prompt diagnosis possible and a new targeted therapy that, so far, has been shown to at least double survival. The complexity of caring for patients with BPDCN stems from both its rarity and its multiorgan involvement. 'Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm' is designed to bring hematologists, oncologists, dermatologists, pathologists, clinical nurse specialists and trainees in all these fields up to speed on the latest developments, as well as providing the most up-to-date information on first-line chemotherapy, consolidation treatments and stem cell transplantation. It will aid readers of all relevant medical disciplines to implement prompt diagnosis and effective management. Table of Contents: • What is BPDCN? Diagnosis • Management • Unmet needs and future directions
| Author | : Graham P. Collins |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 188 |
| Release | : 2023-07-20 |
| Genre | : Medical |
| ISBN | : 3318072869 |
Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.
| Author | : C. Hatton |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 161 |
| Release | : 2018-10-16 |
| Genre | : Medical |
| ISBN | : 1910797952 |
Lymphoma affects all ages. Advances in diagnostic cellular and molecular techniques coupled with new treatment options are improving patient outcomes. This third edition of our bestselling 'Fast Facts: Lymphoma' distills the most important aspects of diagnosis and management into an up-to-date and highly accessible well-illustrated overview that includes: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and histology • a synopsis of current laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology, and updated to include the latest molecular genetic techniques • key aspects of staging and initial therapy • clearly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies and chimeric antigen receptor T cells (CAR T cells) • a practical overview of supportive care for the complications of lymphoma. Written by three lymphoma experts from the UK and USA, 'Fast Facts: Lymphoma' gives an interesting international perspective to this challenging disease. Its clarity and colorful format make it a valuable resource for senior health professionals seeking an accessible update in this area of hemato-oncology, trainee doctors and specialist nurses who are new to it, and individuals affected by lymphoma and seeking more information. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care
| Author | : Justin Loke |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 33 |
| Release | : 2021-01-26 |
| Genre | : Medical |
| ISBN | : 3318068241 |
Conventional methods of detecting disease remission in cancers such as leukemia rely on microscopic analysis of tissue samples. Measurable (or minimal) residual disease (MRD) describes the presence of disease beyond the levels of sensitivity afforded by microscopy. Fast Facts: Measurable Residual Disease describes what is meant by MRD, the opportunities and challenges afforded by its identification and the advantages and disadvantages of the methods used for its detection. Specific examples are given to illustrate the implications of detecting MRD in different disease scenarios, with emphasis on acute myeloid and lymphoblastic leukemias. With the recognition and monitoring of MRD likely to play an increasingly important role in disease prognosis and subsequent treatment direction, this accessible resource is ideal for any healthcare professional wanting to know more about this exciting and fast-moving area. Table of Contents: • What is measurable residual disease? • How is MRD measured? • What is the significance of MRD?
| Author | : Kathryn Foucar |
| Publisher | : Elsevier Health Sciences |
| Total Pages | : 1005 |
| Release | : 2023-09-12 |
| Genre | : Medical |
| ISBN | : 0323879071 |
This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering the full range of nonneoplastic and neoplastic conditions of blood and bone marrow, it incorporates the most recent scientific and technical knowledge in the field to provide a comprehensive overview of all key issues relevant to today's practice. Richly illustrated and easy to use, the third edition of Diagnostic Pathology: Blood and Bone Marrow is a visually stunning, one-stop resource for every practicing pathologist, hematopathologist, oncologist, hematologist, resident, student, or fellow as an ideal day-to-day reference or as a reliable training resource. - Provides practicing pathologists with key details about new entities, newly recognized causes of morphologic change in blood and bone marrow abnormalities, and new strategies for appropriate workup of neoplastic processes—all with a focus on key tests and key differential diagnostic considerations - Helps pathologists recognize unique blood and bone marrow findings that can be an indicator for specific exposures, such as new medications, new targeted therapies, or toxins - Integrates updated technologies, newly recognized disorders, complications/features in blood and bone marrow, new targeted therapies, and the increased use of homeopathic remedies - Contains new chapters covering SARS-CoV-2 infection features in blood and bone marrow, myelodysplastic syndrome (MDS) mimics, blood and bone marrow findings linked to targeted therapies, blood and bone marrow findings linked to other medications, and more - Updates all existing chapters and contains expanded information on T-cell neoplasms in blood and bone marrow and intravascular large B-cell lymphoma in blood and bone marrow - Includes details from the World Health Organization (WHO) fifth edition Classification of Haematolymphoid Tumours and the very latest 2023 International Consensus Classification (ICC) publications, reflecting new and renamed diagnostic entities, tumor classification changes and updates, and terminology changes and updates - Discusses molecular testing strategies based on specific neoplasms and specific differential diagnostic consideration - Clearly delineates numerous genetic disorders often found in blood and bone marrow - Features more than 2,500 superb images, including histology and gross pathology photographs, full-color illustrations and graphics, clinical photographs and radiologic images, and many new tables and charts/algorithms - Employs consistently templated chapters, bulleted content, key facts, a variety of tables, annotated images, pertinent references, and an extensive index for quick, expert reference at the point of care - Includes the enhanced eBook version, which allows you to search all text, figures, and references on a variety of devices
